Get the Stockscreener App
19.71
3.63%
0.69
After Hours:
19.71
Arrivent Biopharma Inc stock is traded at $19.71, with a volume of 297.39K.
It is up +3.63% in the last 24 hours and up +16.28% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$19.02
Open:
$18.93
24h Volume:
297.39K
Relative Volume:
0.87
Market Cap:
$799.61M
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-4.903
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
-2.38%
1M Performance:
+16.28%
6M Performance:
-12.20%
1Y Performance:
-17.15%
1-Day Range:
$18.93
$19.78
1-Week Range:
$18.35
$20.99
52-Week Range:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
19.71 | 765.54M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Infinitum Asset Management LLC Has $38.21 Million Stock Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Applying sector rotation models to ArriVent BioPharma Inc.Gold Moves & Fast Exit Strategy with Risk Control - Newser
Exit strategy if you’re trapped in ArriVent BioPharma Inc.Market Activity Summary & Safe Entry Point Alerts - Newser
Risk vs reward if holding onto ArriVent BioPharma Inc.July 2025 Update & AI Optimized Trading Strategy Guides - Newser
Is this a good reentry point in ArriVent BioPharma Inc.Trade Entry Summary & Precise Buy Zone Identification - Newser
How high can ArriVent BioPharma Inc. stock goGap Down & Comprehensive Market Scan Insights - Newser
Developing predictive dashboards with ArriVent BioPharma Inc. dataQuarterly Portfolio Review & Free Low Drawdown Momentum Trade Ideas - Newser
Will breakout in ArriVent BioPharma Inc. lead to full recoveryJuly 2025 Volume & Fast Moving Market Watchlists - Newser
What to expect from ArriVent BioPharma Inc. in the next 30 daysProfit Target & Growth Focused Entry Point Reports - Newser
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7%Here's Why - MarketBeat
What’s next for ArriVent BioPharma Inc. stock priceWeekly Gains Report & Capital Efficiency Focused Strategies - Newser
Regression analysis insights on ArriVent BioPharma Inc. performanceJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Institutional scanner results for ArriVent BioPharma Inc.Portfolio Risk Report & AI Driven Price Predictions - Newser
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Buy" from Brokerages - MarketBeat
How to monitor ArriVent BioPharma Inc. with trend dashboards2025 Risk Factors & Weekly Setup with ROI Potential - Newser
Advanced analytics toolkit walkthrough for ArriVent BioPharma Inc.July 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Will ArriVent BioPharma Inc. stock go up soonWall Street Watch & Weekly Consistent Profit Watchlists - Newser
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Buy” from Brokerages - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
ArriVent Biopharma presents proof-of-concept data from Phase 1b FURTHER trial - MSN
Will ArriVent BioPharma Inc. benefit from macro trendsPortfolio Gains Summary & Reliable Price Breakout Alerts - Newser
What MACD and RSI say about ArriVent BioPharma Inc.July 2025 WrapUp & Precise Entry and Exit Recommendations - Newser
Intraday pattern recognizer results for ArriVent BioPharma Inc.Earnings Recap Summary & Fast Entry High Yield Stock Tips - Newser
how to monitor arrivent biopharma inc. with trend dashboardsJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - Newser
Is ArriVent BioPharma Inc. stock bottoming out2025 Market Overview & Smart Allocation Stock Reports - Newser
ArriVent reports 16-month PFS for lung cancer drug firmonertinib - Investing.com
ArriVent BioPharma Reports Positive Phase 1b Results for Firmonertinib in EGFR PACC Mutant NSCLC, Anticipates Phase 3 ALPACCA Study Enrollment in 2025 - Quiver Quantitative
16-Month Survival Breakthrough: ArriVent's New Lung Cancer Drug Shows Promising CNS Response in Global Trial - Stock Titan
Analyzing recovery setups for ArriVent BioPharma Inc. investors2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
developing predictive dashboards with arrivent biopharma inc. dataVolume Spike & Proven Capital Preservation Methods - Newser
Real time breakdown of ArriVent BioPharma Inc. stock performance2025 Trade Ideas & High Win Rate Trade Tips - Newser
Should I buy ArriVent BioPharma Inc. stock now2025 Key Lessons & Safe Capital Investment Plans - beatles.ru
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):